Study S001405

A RAndomized trIal Examining the Effect of Subcutaneous Semaglutide on Kidney Transplant Candidacy for Patients With Stage 4-5 CKD or Dialysis-dependent ESKD

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT04741074
Acronym: RAISE-KT
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: TERMINATED
Enrollment: 15
Start: 2021-07-23
Primary completion: 2023-01-31
Lead sponsor: Geisinger Clinic
Conditions: CKD; Diabetic Kidney Disease; Type 2 Diabetes Mellitus in Obese; Obesity; Severe Obesity
Interventions: DRUG:Semaglutide 2 mg/1.5 ml (1.34 mg/ml), prefilled pen-injector for subcutaneous injection solution; DRUG:Placebo 1.5 ml, prefilled pen-injector for subcutaneous injection solution
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: REGISTRY:Universal Trial Number

Registered primary outcomes

Kidney Transplant Eligibility [Ascertained at the end of 9 months]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.